Kenvue Long Term Debt 2020-2024 | KVUE
- Kenvue long term debt for the quarter ending December 31, 2024 was $7.055B, a 8.22% decline year-over-year.
- Kenvue long term debt for 2024 was $7.055B, a 8.22% decline from 2023.
- Kenvue long term debt for 2023 was $7.687B, a 0% decline from 2022.
- Kenvue long term debt for 2022 was $0B, a 0% decline from 2021.
Kenvue Annual Long Term Debt (Millions of US $) |
|
---|---|
2024 | $7,055 |
2023 | $7,687 |
2022 | $0 |
2021 | $0 |
2020 | $0 |
2019 | $0 |
Kenvue Quarterly Long Term Debt (Millions of US $) |
|
---|---|
2024-12-31 | $7,055 |
2024-09-30 | $7,053 |
2024-06-30 | $7,051 |
2024-03-31 | $7,033 |
2023-12-31 | $7,687 |
2023-09-30 | $7,685 |
2023-06-30 | $7,684 |
2023-03-31 | $7,676 |
2022-12-31 | |
2022-09-30 | |
2022-06-30 | |
2022-03-31 | |
2021-12-31 | |
2020-12-31 | |
2019-12-31 |
Sector | Industry | Market Cap | Revenue |
---|---|---|---|
Consumer Staples | CONS PD- MISC STPL | $45.972B | $15.455B |
Kenvue Inc. is a pure-play consumer health company. Its brand portfolio includes AVEENO(R), BAND-AID(R) Brand Adhesive Bandages, JOHNSON'S(R), LISTERINE(R), NEUTROGENA(R), TYLENOL(R) and ZYRTEC(R). Kenvue Inc. is based in SKILLMAN, N.J. |